Clovis Lung Data Wow; PARP Inhibitor Makes Impression, too
Analysts, inspecting early stage data, hailed the "paradigm-changing" potential in the treatment of at least one set of non-small-cell lung cancer (NSCLC) patients with Clovis Oncology Inc.'s oral CO-1686, for which results from Phase I/II trials were reported at ASCO 2013.
Helped also by early data with an ovarian-cancer therapy, Boulder, Colo.-based Clovis' shares (NASDAQ:CLVS) blew through the roof, ending Monday at $74.59, up $38.01 , 104 percent, after trading as high as $86.29.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter